Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 50Lymphoma 30Lung Neoplasms 29Breast Neoplasms 28Prostatic Neoplasms 26Multiple Myeloma 25Melanoma 22Lymphoma, Non-Hodgkin 20Carcinoma, Non-Small-Cell Lung 20Ovarian Neoplasms 19Leukemia, Myeloid, Acute 19Neoplasm Metastasis 18Glioma 18Pancreatic Neoplasms 17Colorectal Neoplasms 16Urinary Bladder Neoplasms 15Hematologic Neoplasms 15Carcinoma, Renal Cell 15Sarcoma 14Burkitt Lymphoma 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Neuroblastoma 13Colonic Neoplasms 12Carcinoma 12Thyroid Neoplasms 11Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Myelodysplastic Syndromes 11Leukemia, Lymphocytic, Chronic, B-Cell 11Ependymoma 11

Interventions

durvalumab 1Pemetrexed 1Paclitaxel 1Gemcitabine 1Cisplatin 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pathologic Complete Response × 30 days × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡